FindTrial
Sign In

Evaluation of role of MRI and CT scan in the internal radiotherapy of cervical cancer for the precise delivery of treatment.

Prospective evaluation of target volume coverage and dose volume histogram parameters of organ at risks by MRI based image guided intracavitary brachytherapy using combined MRI/ CT planning technique with MRI only at first fraction for cervical cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/016911
Enrollment
20
Registered
2019-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C538- Malignant neoplasm of overlappingsites of cervix uteri

Interventions

Intervention1: Intracavitary brachytherapy (ICBT): Each patient will receive 3 fractions of ICBT through mHDR brachytherapy unit of 7Gy each with a gap of one week after each fraction. Subsequent to f

Sponsors

Dr Ram Manohar Lohia Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 25 and 60 years. Histologically proven squamous carcinoma of the uterine cervix of FIGO stage IIA to IIIB. Patient must have completed EBRT. Patient willing to sign the informed consent. Patient should be compatible for MRI pelvis. (No metallic or implant of ferromagnetic substance) KPS > 70 Patient should be fit for General anesthesia (GA) with normal renal function.

Exclusion criteria

Exclusion criteria: Stage IV disease Para-aortic nodes +ve History of any other malignancy within the last 5 years Adenocarcinoma of the cervix Patient suffering from active HIV, Hepatitis B or C. Pregnancy or lactating women

Design outcomes

Primary

MeasureTime frame
Comparison of volumetric doses of target volume and dose volume histogram parameters of organ at risks (rectum, bladder, sigmoid and urethra) achieved with MRI vis-à-vis CT based plansTimepoint: 2 years—

Secondary

MeasureTime frame
To evaluate for acute toxicities (gastrointestinal, genitourinary and vaginal) and loco-regional control ratesTimepoint: At 6 months and 1 year—

Countries

India

Contacts

Public ContactDr Madhup Rastogi

Dr Ram Manohar Lohia Institue of Medical Sciences

drmadhup1@gmail.com9418155955

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026